178 related articles for article (PubMed ID: 24962658)
1. Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer.
Wilson JM; Mukherjee S; Chu KY; Brunner TB; Partridge M; Hawkins M
Radiat Oncol; 2014 Jun; 9():146. PubMed ID: 24962658
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy.
Choi HJ; Lee JW; Kang B; Song SY; Lee JD; Lee JH
Yonsei Med J; 2014 Nov; 55(6):1498-506. PubMed ID: 25323885
[TBL] [Abstract][Full Text] [Related]
3. Correlation of
Wilson JM; Mukherjee S; Brunner TB; Partridge M; Hawkins MA
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):370-377. PubMed ID: 28190636
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
Parlak C; Topkan E; Onal C; Reyhan M; Selek U
Radiat Oncol; 2012 Mar; 7():37. PubMed ID: 22429939
[TBL] [Abstract][Full Text] [Related]
5. High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.
Calais J; Dubray B; Nkhali L; Thureau S; Lemarignier C; Modzelewski R; Gardin I; Di Fiore F; Michel P; Vera P
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):858-67. PubMed ID: 25680400
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy.
Topkan E; Parlak C; Kotek A; Yapar AF; Pehlivan B
BMC Gastroenterol; 2011 Nov; 11():123. PubMed ID: 22074002
[TBL] [Abstract][Full Text] [Related]
7. Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation.
Aerts HJ; Bussink J; Oyen WJ; van Elmpt W; Folgering AM; Emans D; Velders M; Lambin P; De Ruysscher D
Lung Cancer; 2012 Jan; 75(1):73-6. PubMed ID: 21782272
[TBL] [Abstract][Full Text] [Related]
8. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
9. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
Tan S; Kligerman S; Chen W; Lu M; Kim G; Feigenberg S; D'Souza WD; Suntharalingam M; Lu W
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1375-82. PubMed ID: 23219566
[TBL] [Abstract][Full Text] [Related]
10. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
Klayton T; Li T; Yu JQ; Keller L; Cheng J; Cohen SJ; Meropol NJ; Scott W; Xu-Welliver M; Konski A
J Gastrointest Cancer; 2012 Dec; 43(4):612-8. PubMed ID: 22777832
[TBL] [Abstract][Full Text] [Related]
11. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
[TBL] [Abstract][Full Text] [Related]
12. Use of
Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
[No Abstract] [Full Text] [Related]
13. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses.
Nkhali L; Thureau S; Edet-Sanson A; Doyeux K; Benyoucef A; Gardin I; Michel P; Vera P; Dubray B
Acta Oncol; 2015 Jun; 54(6):909-15. PubMed ID: 25417733
[TBL] [Abstract][Full Text] [Related]
14. ¹⁸F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose.
Massaccesi M; Calcagni ML; Spitilli MG; Cocciolillo F; Pelligrò F; Bonomo L; Valentini V; Giordano A
Radiat Oncol; 2012 Jul; 7():106. PubMed ID: 22781363
[TBL] [Abstract][Full Text] [Related]
15. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
16. Consequences of additional use of contrast-enhanced (18)F-FDG PET/CT in target volume delineation and dose distribution for pancreatic cancer.
Li XX; Liu NB; Zhu L; Yuan XK; Yang CW; Ren P; Gong LL; Zhao LJ; Xu WG; Wang P
Br J Radiol; 2015 Jul; 88(1051):20140590. PubMed ID: 25939819
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
[TBL] [Abstract][Full Text] [Related]
18. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.
Capirci C; Rampin L; Erba PA; Galeotti F; Crepaldi G; Banti E; Gava M; Fanti S; Mariani G; Muzzio PC; Rubello D
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1583-93. PubMed ID: 17503039
[TBL] [Abstract][Full Text] [Related]
19. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
20. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]